Connect with us

Headlines

Allergan Will Say No Thanks to $46 Billion Take-Over Bid

mm

Published

on

The company says Valeant would cut back on research.

Reports say that Botox-maker Allergan this week will reject the $46 billion take-over offer from rival Valeant Pharmaceuticals, which recently acquired Bausch & Lomb, setting the stage for what the Financial Times calls “a hostile takeover battle at the top of the US drugmaking industry.” Allergan is expected to raise concerns that Valeant would cut research and development as a reason for refusing the offer. The acquisition would create the pre-eminent global powerhouse in the eyecare industry.

Read more at Financial Times |
Toronto Star

SPONSORED VIDEO

Get the Practice of Your Dreams With Omg! Optical Marketing Group

This high volume practice had outgrown their ultra successful location and needed expansion. The idea was big, just like Texas! Design a fusion concept that featured optometry, aesthetics, fitness + wellness. Mission accomplished. Download the Free Lookbook.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Advertisement

Most Popular